Adjudicada
Sum medicamentos exclusivos de las firmas: Astellas Pharma, Astrazeneca Farmaceutica, Laboratorios Almirall, S.A:, Ipsen Pharma, Janssen-Cilag, Lilly, Merck, Vilfor Pharma España, Biogen Spain, Eisai Farmaceuticas, Gilead-Sciences, Novartis Farmaceutica, y Sanofi-Aventis
Gerencia de Atención Integrada de Cuenca
- Importe adjudicado19.667.760 €
- Plazo de presentación17/06/2022
- ProcedimientoNegociado con publicidad
- CPV33690000
- Obras
Fechas clave
- Fin de plazo de presentación17/06/2022
- Adjudicación10/10/2022
- Anuncio de licitación20/10/2022
- Hoy07/07/2026
Datos del contrato
- Código NUTS
- ES423
Lotes
| Lote | Título | Importe |
|---|---|---|
| 01 | Astellas Pharma, s.a. | 97.643 € |
| 01 | Astellas Pharma, s.a. | 97.643 € |
| 01 | Astellas Pharma, s.a. | 97.643 € |
| 01 | Astellas Pharma, s.a. | 97.643 € |
| 01 | Astellas Pharma, s.a. | 97.643 € |
| 01 | Astellas Pharma, s.a. | 97.643 € |
| 01 | Astellas Pharma, s.a. | 97.643 € |
| 02 | Astrazeneca Farmaceutica Spain, s.a. | 197.102 € |
| 02 | Astrazeneca Farmaceutica Spain, s.a. | 197.102 € |
| 02 | Astrazeneca Farmaceutica Spain, s.a. | 197.102 € |
| 02 | Astrazeneca Farmaceutica Spain, s.a. | 197.102 € |
| 02 | Astrazeneca Farmaceutica Spain, s.a. | 197.102 € |
| 02 | Astrazeneca Farmaceutica Spain, s.a. | 197.102 € |
| 02 | Astrazeneca Farmaceutica Spain, s.a. | 197.102 € |
| 03 | Laboratorios Almirall, S.A. | 39.479 € |
| 03 | Laboratorios Almirall, S.A. | 39.479 € |
| 03 | Laboratorios Almirall, S.A. | 39.479 € |
| 03 | Laboratorios Almirall, S.A. | 39.479 € |
| 03 | Laboratorios Almirall, S.A. | 39.479 € |
| 03 | Laboratorios Almirall, S.A. | 39.479 € |
| 03 | Laboratorios Almirall, S.A. | 39.479 € |
| 04 | Ipsen Pharma, s.a. | 77.040 € |
| 04 | Ipsen Pharma, s.a. | 77.040 € |
| 04 | Ipsen Pharma, s.a. | 77.040 € |
| 04 | Ipsen Pharma, s.a. | 77.040 € |
| 04 | Ipsen Pharma, s.a. | 77.040 € |
| 04 | Ipsen Pharma, s.a. | 77.040 € |
| 04 | Ipsen Pharma, s.a. | 77.040 € |
| 05 | Janssen-Cilag, s.a. | 890.845 € |
| 05 | Janssen-Cilag, s.a. | 890.845 € |
| 05 | Janssen-Cilag, s.a. | 890.845 € |
| 05 | Janssen-Cilag, s.a. | 890.845 € |
| 05 | Janssen-Cilag, s.a. | 890.845 € |
| 05 | Janssen-Cilag, s.a. | 890.845 € |
| 05 | Janssen-Cilag, s.a. | 890.845 € |
| 06 | Lilly, s.a. | 116.472 € |
| 06 | Lilly, s.a. | 116.472 € |
| 06 | Lilly, s.a. | 116.472 € |
| 06 | Lilly, s.a. | 116.472 € |
| 06 | Lilly, s.a. | 116.472 € |
| 06 | Lilly, s.a. | 116.472 € |
| 06 | Lilly, s.a. | 116.472 € |
| 07 | Merck, s.l. | 268.582 € |
| 07 | Merck, s.l. | 268.582 € |
| 07 | Merck, s.l. | 268.582 € |
| 07 | Merck, s.l. | 268.582 € |
| 07 | Merck, s.l. | 268.582 € |
| 07 | Merck, s.l. | 268.582 € |
| 07 | Merck, s.l. | 268.582 € |
| 08 | Vifor Pharma España, s.l.u. | 246.700 € |
| 08 | Vifor Pharma España, s.l.u. | 246.700 € |
| 08 | Vifor Pharma España, s.l.u. | 246.700 € |
| 08 | Vifor Pharma España, s.l.u. | 246.700 € |
| 08 | Vifor Pharma España, s.l.u. | 246.700 € |
| 08 | Vifor Pharma España, s.l.u. | 246.700 € |
| 08 | Vifor Pharma España, s.l.u. | 246.700 € |
| 09 | Biogen Spain, s.l.u. | 389.231 € |
| 09 | Biogen Spain, s.l.u. | 389.231 € |
| 09 | Biogen Spain, s.l.u. | 389.231 € |
| 09 | Biogen Spain, s.l.u. | 389.231 € |
| 09 | Biogen Spain, s.l.u. | 389.231 € |
| 09 | Biogen Spain, s.l.u. | 389.231 € |
| 09 | Biogen Spain, s.l.u. | 389.231 € |
| 10 | Eisai Farmaceutica, s.a. | 17.535 € |
| 10 | Eisai Farmaceutica, s.a. | 17.535 € |
| 10 | Eisai Farmaceutica, s.a. | 17.535 € |
| 10 | Eisai Farmaceutica, s.a. | 17.535 € |
| 10 | Eisai Farmaceutica, s.a. | 17.535 € |
| 10 | Eisai Farmaceutica, s.a. | 17.535 € |
| 10 | Eisai Farmaceutica, s.a. | 17.535 € |
| 11 | Gilead-Sciences, s.l. | 206.620 € |
| 11 | Gilead-Sciences, s.l. | 206.620 € |
| 11 | Gilead-Sciences, s.l. | 206.620 € |
| 11 | Gilead-Sciences, s.l. | 206.620 € |
| 11 | Gilead-Sciences, s.l. | 206.620 € |
| 11 | Gilead-Sciences, s.l. | 206.620 € |
| 11 | Gilead-Sciences, s.l. | 206.620 € |
| 12 | Novartis Farmaceutica, s.a. | 1.484.310 € |
| 12 | Novartis Farmaceutica, s.a. | 1.484.310 € |
| 12 | Novartis Farmaceutica, s.a. | 1.484.310 € |
| 12 | Novartis Farmaceutica, s.a. | 1.484.310 € |
| 12 | Novartis Farmaceutica, s.a. | 1.484.310 € |
| 12 | Novartis Farmaceutica, s.a. | 1.484.310 € |
| 12 | Novartis Farmaceutica, s.a. | 1.484.310 € |
| 13 | Sanofi-Aventis s.a.u. | 317.144 € |
| 13 | Sanofi-Aventis s.a.u. | 317.144 € |
| 13 | Sanofi-Aventis s.a.u. | 317.144 € |
| 13 | Sanofi-Aventis s.a.u. | 317.144 € |
| 13 | Sanofi-Aventis s.a.u. | 317.144 € |
| 13 | Sanofi-Aventis s.a.u. | 317.144 € |
| 13 | Sanofi-Aventis s.a.u. | 317.144 € |